Prothena (PRTA)

Prothena Corporation plc owns a drug discovery business platform, focused on identifying and translating targets into potential therapies for chronic degenerative and other related disease areas. It was formerly known as Neotope Corporation Limited and changed its name in October 2012. The company was incorporated in 2012 and is based in Dublin, Ireland. Prothena Corporation plc (NasdaqGM:PRTA) operates independently of Elan Corporation, plc as of December 20, 2012.

Description

Prothena Corporation plc is a biotechnology company. The Company focuses on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease causing proteins. The potential therapies have a range of indications, including AL and AA forms of amyloidosis, Parkinson’s disease and related synucleinopathies, and cell adhesion targets involved in inflammatory disease and metastatic cancers. The Company’s program is an antibody being investigated for the potential treatment of AL Amyloidosis. The Company’s portfolio of targets also includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy Body Dementia and Parkinson’s disease, tau for Alzheimer’s disease and other tauopathies, and a program for Type 2 Diabetes. The Company’s programs include NEOD001 for Amyloidosis, NEOD002 for Parkinson's Disease, MCAM for Inflammatory Disease and Metastatic Cancer, Tau for Alzheimer's Disease and Type 2 Diabetes.

Key stats and ratios

	Q1 (Mar '13)	2012
Net profit margin	-5234.50%	-1557.98%
Operating margin	-5243.86%	-1557.94%
EBITD margin	-	-1540.33%
Return on average assets	-28.32%	-62.32%
Return on average equity	-29.40%	-68.99%
Employees	30	-

Address

25-28 NORTH WALL QUAY, DUBLIN 1
DUBLIN, CA 94080
Ireland

Website links 

www.prothena.com